This clinical trial investigates the maximum tolerated dosage of tucatinib combined with ado-trastuzumab emtansine in the treatment of patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases.
https://ift.tt/2IzAvjm
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου